LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: LabCorp is a leading provider of clinical laboratory testing services. The quarter was marked by the consolidation of its Ontario, Canada joint venture (effective Jan 1, 2008) and continued execution of its strategic plan to expand in routine and genomic testing.

Key Financial Metrics

Note: Total Debt calculated as Short-term borrowings ($618.4) + Long-term debt ($1,064.9) for Q1 2008.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.5% to $1,103.2 million. This was driven primarily by the inclusion of $64.1 million in revenue from the newly consolidated Ontario, Canada joint venture. Excluding this acquisition, organic growth was 1.6% in volume and 2.5% in price.
• Profitability: Operating income rose 18.5% to $241.1 million. Net earnings increased 6.4% to $130.3 million.
• Cost Structure: Cost of sales increased 9.7%. Excluding the Canada operation, cost of sales as a percentage of net sales rose slightly from 57.8% to 58.1% due to infrastructure investments and test mix shifts. SG&A expenses increased to $215.6 million but improved as a percentage of sales (19.8% vs 20.5% excluding Canada) due to cost controls.
• Interest Expense: Increased significantly to $19.9 million from $12.6 million, primarily due to borrowings under the $500 million Term Loan Facility initiated in late 2007.
• Investment Income: Income from joint venture partnerships dropped to $4.4 million from $16.4 million because the Ontario operation is now consolidated rather than accounted for via the equity method.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects 2008 capital expenditures to range between $120 million and $140 million, funded by operating cash flow and credit facilities.
• UnitedHealthcare Agreement: Under a 10-year exclusive provider agreement, LabCorp committed to reimburse UnitedHealthcare up to $200 million for transition costs over the first three years. Management estimates the total commitment will be approximately $115 million based on current trends.
• Debt and Liquidity: The company maintains a $500 million Term Loan and a Revolving Credit Facility. As of March 31, 2008, $20.0 million was drawn on the revolver. The company entered an interest rate swap to hedge variable rate risk on the term loan.
• Convertible Securities: Holders of Zero-Coupon Subordinated Notes and LYONs may convert these securities through June 30, 2008. Contingent cash interest of approximately $1.31 per note is expected to be paid in September 2008.
• Risk Factors: Key risks include changes in federal/state reimbursement policies, regulatory investigations (Medicare/Medicaid), competition, and the impact of the economy on patient deductibles and collectibility (bad debt expense rose to 5.0% of sales).

Investor Verification Checklist

• Consolidation Impact: Verify the sustainability of revenue growth by analyzing performance excluding the $64.1 million from the Ontario, Canada consolidation.
• UnitedHealthcare Costs: Monitor the actual transition cost reimbursements against the $115 million estimated total commitment.
• Convertible Debt Conversion: Assess the potential dilution or cash outflow if holders exercise conversion rights on the Zero-Coupon Notes and LYONs by the June 30, 2008 deadline.
• Bad Debt Trends: Review the 5.0% bad debt expense ratio to determine if economic headwinds are impacting cash collections from patients.
• Share Repurchases: Note that the company repurchased $55.7 million of stock in Q1, with $370.1 million of authorization remaining.